Results 21 to 30 of about 982 (100)

Clinical Outcomes of Peptide Receptor Radionuclide Therapy in Japanese Patients with Metastatic Rectal Neuroendocrine Tumors. [PDF]

Cancers (Basel)
Iizuka T, Kobayashi N, Wild D, Kaul F, Suzuki H, Maehara K, Okubo N, Tsuyuki S, Takano S, Kurita Y, Yoneda M, Ichikawa Y.   +11 more
europepmc   +1 more source

Morphological versus spherical cellular geometry models: impact on dose-response of CA20948 cells to ¹⁷⁷Lu- and ¹⁶¹Tb-labeled DOTA-TATE and DOTA-LM3. [PDF]

EJNMMI Phys
Spoormans K, Crabbé M, Struelens L, Koole M.   +3 more
europepmc   +1 more source

Radiopharmaceutical: An Update and Comparison of Preclinical Investigation Result of Alpha and Beta Emitter Radioisotope. [PDF]

Drug Des Devel Ther
Luhung A, Hasanah AN, Ramdhani D.
europepmc   +1 more source

CD70-targeted platform for diagnosing and treating multiple myeloma. [PDF]

J Immunother Cancer
Li J, Yan H, Wang X, Zhang Y, Chen P, Feng J, Zhang R, Li Z, Huang Z, Xu C, Ma N, Lin X, Zhao M, Zhu W, Peng Q, Xie S, Wei W, Dong M.   +17 more
europepmc   +1 more source

Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial. [PDF]

Front Endocrinol (Lausanne)
Kolodziej M, Opalinska M, Mikolajczak R, Hubalewska-Dydejczyk A, Dedecjus M, Kowalska A, Saracyn M, Garnuszek P, Cieszykowska I, Januszkiewicz-Caulier J, Dlugosinska J, Durma AD, Jozwik-Plebanek K, Mroz A, Janiak K, Gasior-Perczak D, Trofimiuk-Muldner M, Sowa-Staszczak A, Braziewicz J, Lenda-Tracz W, Kacperski K, Budzynska A, Kubik A, Pastusiak P, Chalewska W, Borkowska A, Cegla P, Walecka-Mazur A, Szczodry A, Kaminski G.   +29 more
europepmc   +1 more source

Drug interactions involving therapeutic radiopharmaceuticals: a systematic review. [PDF]

EJNMMI Radiopharm Chem
Gacon R, Chapuis R, Fabris-Davet L, Ranjit N, Goutelle S, Bourguignon L, Flaus A, Bolot C, Levigoureux E, Gallet M, Chaib S.   +10 more
europepmc   +1 more source

Alpha Therapy Beyond TOC and TATE-Production, Quality Control, and In-Human Results for the SSTR2 Antagonist DOTA-LM3. [PDF]

Pharmaceuticals (Basel)
Greifenstein L, Martin M, Stephan S, Eismant A, Kramer CS, Landvogt C, Mueller C, Rösch F, Baum RP.   +8 more
europepmc   +1 more source

PARP Inhibitors as Radiosensitizers: Current Evidence and Future Directions. [PDF]

Curr Oncol Rep
Pereira E, Pereira F, Campos G, Abrantes AM, Botelho MF, Silva-Vaz P, Pires AS.   +6 more
europepmc   +1 more source

Radioligand therapy for primary brain tumors: a PRISMA-based systematic review of meningiomas and gliomas. [PDF]

Front Med (Lausanne)
Grassi I, Sansovini M, Matteucci F, Marini I, Caroli P, Celli M, Fantini L, Rossetti V, Gurrieri L, Riva N, Rossi A, Bronico I, Iorio VD, Sarnelli A, Arpa D, Nicolini S.   +15 more
europepmc   +1 more source

First Real-World Evidence on the Safety and Effectiveness of Lutathera^TM for Treating Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Insights from Post-Marketing Surveillance. [PDF]

Cancers (Basel)
Kim YI, Suh HY, Kang Y, Cho H, Hyun SH, Song YS, Ha S, Kang KW.   +7 more
europepmc   +1 more source